Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

Chapel Hill drugmaker halts trials, executives depart after raising $425M

Summary by The Business Journals
Areteia Therapeutics appears to be winding down after terminating multiple Phase 3 asthma drug trials and losing its CEO and CFO. The Chapel Hill biotech had raised $425 million to develop an oral asthma therapy, but federal records show trials were halted after benefits no longer justified continued development.

1 Articles

The Business JournalsThe Business Journals
Center

Chapel Hill drugmaker halts trials, executives depart after raising $425M

Areteia Therapeutics appears to be winding down after terminating multiple Phase 3 asthma drug trials and losing its CEO and CFO. The Chapel Hill biotech had raised $425 million to develop an oral asthma therapy, but federal records show trials were halted after benefits no longer justified continued development.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Business Journals broke the news in United States on Wednesday, December 17, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Chapel Hill, North Carolina icon

Chapel Hill, North Carolina

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal